Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26205294 | 0.81 | KDM2B (0.36) | KCNH2 | |
| SCHEMBL12537075 | 0.80 | NCF1 (0.42) | HRH3KCNH2FBP1HTR4 | |
| SCHEMBL23277754 | 0.80 | TSHR (0.42) | HRH3KCNH2 | |
| SCHEMBL10241735 | 0.77 | SMN1; SMN2 (0.42) | HRH3FBP1 | |
| SCHEMBL11520489 | 0.77 | — | — | |
| SCHEMBL12026457 | 0.74 | HRH3 (0.40) | HRH3KCNH2 | |
| SCHEMBL22309868 | 0.74 | HRH3 (0.40) | HRH3KCNH2 | |
| SCHEMBL8266837 | 0.74 | HRH3 (0.40) | HRH3 | |
| SCHEMBL3429348 | 0.73 | FBP1 (0.43) | FBP1 | |
| SCHEMBL681678 | 0.73 | HRH3 (0.41) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399259-A1 | Phosphonamidates that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer | UNITY BIOTECHNOLOGY, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10738042-B2 | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | UNITY BIOTECHNOLOGY, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190330199-A1 | Phosphonamidates that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated By Senescent Cells and for Treating Cancer | UNITY BIOTECHNOLOGY, INC. | 2019-10-31 | — | — | US | disclosed |
| US-8119654-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7652028-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | INOTEK PHARMACEUTICALS CORPORATION | 2010-01-07 | — | — | US | disclosed |
| WO-2007025009-A2 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330199-A1 | Phosphonamidates that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated By Senescent Cells and for Treating Cancer | BAX, BCL2, TP53 | HRH3 4867/4885KCNH2 4801/4885FBP1 1650/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | HRH3 3631/4885KCNH2 874/4885FBP1 3604/4885 |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | HRH3 3631/4885KCNH2 874/4885FBP1 3604/4885 |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | TNNI3, IDH2, GLS | HRH3 3631/4885KCNH2 874/4885FBP1 3604/4885 |
| US-20200399259-A1 | Phosphonamidates that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer | BAX, BCL2, TP53 | HRH3 4867/4885KCNH2 4801/4885FBP1 1650/4885 |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | HRH3 3631/4885KCNH2 874/4885FBP1 3604/4885 |
| US-10738042-B2 | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | BAX, BCL2, TP53 | HRH3 4853/4885KCNH2 4801/4885FBP1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.